Study #2020-1170
Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients with Pulmonary Impairment
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD). The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements. A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pulmonary;Pneumonia;Hematopoietic System--Cancer
Study phase:
Physician name:
Ajay Sheshadri
Department:
Pulmonary Medicine
For general questions about clinical trials:
1-855-922-5134
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.